IgM MGUS and Waldenstrom-associated anti-MAG neuropathies display similar response to rituximab therapy

Campagnolo, Marta; Zambello, Renato; Nobile‐Orazio, Eduardo; Benedetti, Luana; Marfia, Girolama Alessandra; Riva, Nilo; Castellani, Francesca; Bianco, Mariangela; Salvalaggio, Alessandro; Garnero, Martina; Ruiz, Marta; Mataluni, Giorgia; Fazio, Raffaella; Ermani, Mario; Briani, Chiara

doi:10.1136/jnnp-2017-315736

Cited by 28 publications

(19 citation statements)

References 5 publications

(2 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Response to treatment was not different according to haematological condition 15. Clinical prolonged stabilisation after rituximab may be considered as a partial response in this potentially progressive disabling pathology and appears as an interesting point to focus on long-term prospective and controlled study.…”

Section: Discussionmentioning

confidence: 86%

Anti-MAG antibodies in 202 patients: clinicopathological and therapeutic features

Svahn¹,

Petiot²,

Antoine³

et al. 2017

J Neurol Neurosurg Psychiatry

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 86%

Anti-MAG antibodies in 202 patients: clinicopathological and therapeutic features

Svahn¹,

Petiot²,

Antoine³

et al. 2017

J Neurol Neurosurg Psychiatry

View full text Add to dashboard Cite

show abstract

“…In anti‐MAG antibody neuropathies, evidence from trials of immunotherapies is inadequate to recommend any particular treatment . However, data from approximately 200 patients treated in the last 15 years show that rituximab helped 30% to 50% of the patients, with WM showing the same rate of response as patients with IgM MGUS …”

Section: Neuropathies In Low‐grade Nhlmentioning

confidence: 99%

“…29 However, data from approximately 200 patients treated in the last 15 years show that rituximab helped 30% to 50% of the patients, 30 with WM showing the same rate of response as patients with IgM MGUS. 31 Therapeutic option should therefore consider rituximab, as a cornerstone of the therapy, in combination with chemotherapy such as bendamustine or cyclophosphamide, as from WM guidelines.…”

Section: Waldenström's Macroglobulinemiamentioning

confidence: 99%

Peripheral nervous system involvement in lymphomas

Briani

Visentin

Campagnolo

et al. 2019

J Peripheral Nervous Sys

Self Cite

View full text Add to dashboard Cite

The peripheral nervous system may be involved at any stage in the course of lymphoproliferative diseases. The different underlying mechanisms include neurotoxicity secondary to chemotherapy, direct nerve infiltration (neurolymphomatosis), infections, immune‐mediated, paraneoplastic or metabolic processes and nutritional deficiencies. Accordingly, the clinical features are heterogeneous and depend on the localization of the damage (ganglia, roots, plexi, and peripheral nerves) and on the involved structures (myelin, axon, and cell body). Some clinical findings, such a focal or diffuse involvement, symmetric or asymmetric pattern, presence of pain may point to the correct diagnosis. Besides a thorough medical history and neurological examination, neurophysiological studies, cerebrospinal fluid analysis, nerve biopsy (in selected patients with suspected lymphomatous infiltration) and neuroimaging techniques (magnetic resonance neurography and nerve ultrasound) may be crucial for a proper diagnostic workup.

show abstract

“…26 Small series have demonstrated benefit of rituximab in the treatment of MGUS anti-MAGrelated neuropathy. 32…”

Section: Monoclonal Gammopathymentioning

confidence: 99%

Neuropathy of Connective Tissue Diseases and Other Systemic Diseases

Jin

Shin

2019

Semin Neurol

View full text Add to dashboard Cite

Peripheral neuropathy is associated with numerous systemic diseases. It is often the heralding finding, which can lead to earlier diagnoses and better outcomes. An understanding of the epidemiology and clinical features of these diseases is paramount to their diagnosis and management. This article will focus on neuropathy associated with connective tissue diseases, monoclonal gammopathies, paraneoplastic disorders, medications including chemotherapeutic agents, nutritional deficiencies, alcohol, and toxins.

show abstract

IgM MGUS and Waldenstrom-associated anti-MAG neuropathies display similar response to rituximab therapy

Cited by 28 publications

References 5 publications

Anti-MAG antibodies in 202 patients: clinicopathological and therapeutic features

Anti-MAG antibodies in 202 patients: clinicopathological and therapeutic features

Peripheral nervous system involvement in lymphomas

Neuropathy of Connective Tissue Diseases and Other Systemic Diseases

Contact Info

Product

Resources

About